A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Peccianti C, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavo SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Stingeni L, Caruso C, Argenziano G; Dupilumab Italian National Access Program (Dup-INAP Group)..
Fargnoli MC, et al. Among authors: cannavo sp.
J Dermatolog Treat. 2022 Mar;33(2):1146-1149. doi: 10.1080/09546634.2020.1773379. Epub 2020 Jul 3.
J Dermatolog Treat. 2022.
PMID: 32436765
Free article.
No abstract available.